UNSPSC 51373434: Chlorpheniramine/hydrocodone/pseudoephedrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373434 Chlorpheniramine/hydrocodone/pseudoephedrine is a Commodity code that covers pharmaceutical products state and local governments procure for emergency response, community health, and public health initiatives. Recent solicitations show buying bodies acquiring naloxone kits, safe drug deactivation systems, and generic multi-source pharmaceuticals including over-the-counter products through both direct purchase and cooperative purchasing agreements. Issuing bodies include county health departments and state-administered cooperative purchasing alliances that aggregate demand across multiple member jurisdictions. The procurement scope emphasizes compliance with current Good Manufacturing Practices, the Drug Supply Chain Security Act, FDA requirements, and federal funding conditions when applicable; vendors typically must work through authorized wholesalers or pharmaceutical distributors and maintain detailed product data including National Drug Codes, unit pricing, and pricing flexibility options.

Recent activity spans Florida and Minnesota through multi-state cooperative vehicles. Seminole County, Florida issued IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries to the Seminole County Community Health Building in Sanford, with a two-year initial term and one-year renewal option. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) to establish multi-award contracts for generic pharmaceuticals and OTC products across participating state and local government facilities in Minnesota and Oregon, requiring vendors to supply through authorized wholesalers AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson, with contract effectiveness July 1, 2026. Evaluation criteria for MMCAP weighted price competitiveness at 75 percent, fixed pricing at 10 percent, and administrative compliance factors at 15 percent combined.